NVV1 Stock Overview
A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Novavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.20 |
| 52 Week High | US$23.93 |
| 52 Week Low | US$3.33 |
| Beta | 2.09 |
| 11 Month Change | -8.16% |
| 3 Month Change | -17.78% |
| 1 Year Change | 64.43% |
| 33 Year Change | -95.23% |
| 5 Year Change | 88.07% |
| Change since IPO | -85.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| NVV1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 12.0% | -0.7% | 0.2% |
| 1Y | 64.4% | -17.2% | 8.5% |
Return vs Industry: NVV1 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: NVV1 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| NVV1 volatility | |
|---|---|
| NVV1 Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: NVV1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NVV1's weekly volatility has decreased from 20% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,543 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Novavax, Inc. Fundamentals Summary
| NVV1 fundamental statistics | |
|---|---|
| Market cap | €1.30b |
| Earnings (TTM) | -€273.55m |
| Revenue (TTM) | €850.05m |
1.5x
P/S Ratio-4.8x
P/E RatioIs NVV1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVV1 income statement (TTM) | |
|---|---|
| Revenue | US$885.19m |
| Cost of Revenue | US$769.73m |
| Gross Profit | US$115.46m |
| Other Expenses | US$400.32m |
| Earnings | -US$284.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.78 |
| Gross Margin | 13.04% |
| Net Profit Margin | -32.18% |
| Debt/Equity Ratio | -32.2% |
How did NVV1 perform over the long term?
See historical performance and comparison